Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Purchased by Cutter Capital Management LP

Cutter Capital Management LP lifted its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 61.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 301,623 shares of the biopharmaceutical company's stock after buying an additional 115,000 shares during the quarter. Agios Pharmaceuticals accounts for 4.1% of Cutter Capital Management LP's portfolio, making the stock its 12th biggest holding. Cutter Capital Management LP owned 0.53% of Agios Pharmaceuticals worth $9,911,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Venturi Wealth Management LLC purchased a new position in shares of Agios Pharmaceuticals during the 4th quarter worth approximately $33,000. Wingate Wealth Advisors Inc. acquired a new position in shares of Agios Pharmaceuticals during the 4th quarter valued at $53,000. Sterling Capital Management LLC grew its stake in shares of Agios Pharmaceuticals by 818.0% in the fourth quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company's stock valued at $59,000 after buying an additional 1,587 shares in the last quarter. KBC Group NV raised its stake in shares of Agios Pharmaceuticals by 30.5% during the fourth quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company's stock valued at $86,000 after purchasing an additional 611 shares during the period. Finally, AlphaQuest LLC grew its stake in shares of Agios Pharmaceuticals by 106.2% during the fourth quarter. AlphaQuest LLC now owns 4,540 shares of the biopharmaceutical company's stock valued at $149,000 after acquiring an additional 2,338 shares in the last quarter.

Agios Pharmaceuticals Stock Performance

Shares of AGIO stock opened at $29.97 on Tuesday. The firm's 50 day moving average price is $29.72 and its two-hundred day moving average price is $37.65. The stock has a market cap of $1.74 billion, a PE ratio of 2.64 and a beta of 0.83. Agios Pharmaceuticals, Inc. has a 52-week low of $23.42 and a 52-week high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last posted its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.80) by $0.25. Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. The firm had revenue of $8.73 million during the quarter, compared to analysts' expectations of $9.86 million. As a group, sell-side analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Agios Pharmaceuticals news, Director Jacqualyn A. Fouse sold 7,497 shares of the company's stock in a transaction on Thursday, April 10th. The shares were sold at an average price of $25.90, for a total value of $194,172.30. Following the transaction, the director now directly owns 149,220 shares in the company, valued at $3,864,798. The trade was a 4.78 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 4.93% of the company's stock.

Analyst Ratings Changes

A number of research firms have commented on AGIO. Scotiabank decreased their price objective on shares of Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating for the company in a report on Friday. StockNews.com raised Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Thursday, May 1st. Finally, HC Wainwright initiated coverage on shares of Agios Pharmaceuticals in a research note on Monday, February 24th. They set a "buy" rating and a $58.00 price objective on the stock. Five investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $56.00.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.